Press releases

Karo Healthcare appoints Egil Mølsted Madsen as CFO

We are pleased to announce that Egil Mølsted Madsen will assume the role of CFO at Karo starting on 3 October 2024. Egil, a Danish national, brings a wealth of…

Karo Group publishes the 2023 Sustainability Report

Today, on 15 April 2024, Karo Group* is publishing its 2023 Sustainability Report on the company’s website, www.karohealthcare.com. For further information, please contact: Christoffer Lorenzen, CEO, +46 735 017 620,…

Karo Healthcare expands its presence in Italy with the acquisition of the rights to Proctosedyl® from Bayer

Karo Healthcare AB (‘Karo’) announces the acquisition of the rights to the OTC brand Proctosedyl from Bayer. The transaction transfers global dossier ownership to the OTC pharmaceutical Proctosedyl, and exclusive…

Karo Healthcare completes the acquisition of the rights to the Global OTC brand Lamisil® from Haleon

Karo Healthcare (‘Karo’) has today completed the previously announced acquisition of the rights to the Global OTC brand Lamisil® from Haleon UK Holdings Ltd. (‘Haleon’) for a total consideration of…

Karo Healthcare acquires the Global OTC brand Lamisil® from Haleon

Karo Healthcare (‘Karo’) announces the acquisition of the rights to the Global OTC brand Lamisil® from Haleon UK Holdings Ltd. (‘Haleon’) for a total consideration of GBP 235m (EUR 274m)…

Babak Peyami Joins Karo’s Corporate Management Team as new Head of Digital Commerce

Karo Healthcare announces changes to its Corporate Management Team. Robin List transitions to an advisory role and Babak Peyami is promoted to drive Karo’s digital commerce activities. Babak joined Karo…

Karo Healthcare publishes the 2022 Sustainability Report

Today, on 24 April 2023, Karo Healthcare is publishing its first separate Sustainability Report on the company’s website, www.karohealthcare.com. For further information, please contact: Christoffer Lorenzen, CEO, +46 735 017…

Michael Kaltenborn appointed CSDO at Karo

Karo Healthcare (“Karo”) has appointed Michael Kaltenborn as Chief Strategy & Corporate Development Officer (CSDO). The appointment of Michael Kaltenborn reflects Karo’s ambition to grow via M&A and to continue…

Karo Pharma Aktiebolag’s application for de-listing has been approved

Karo Pharma Aktiebolag’s (“Karo Pharma” or the “Company”) application for de-listing has now been approved by Nasdaq. The last day of trading in Karo Pharma’s share on Nasdaq First North Growth Market will be 24 November 2022.

Karo Pharma Aktiebolag applies for de-listing

The Board of Directors of Karo Pharma Aktiebolag (“Karo Pharma” or the “Company”) has resolved to apply for de-listing of the Company’s shares from Nasdaq First North Growth Market following…